Aviceda Therapeutics Appoints Biopharma and Business Veterans Chris Adams, PhD, MBA, and Nancy K. Thomason, MBA to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics is a pre-clinical stage biotech company focused on the next generation of glycol-immune therapeutics utilizing the Glyco-Code technology to address the innate immune system and chronic non-resolving inflammation. Today, the company is excited to announce the appointment of two biopharma and business veterans to their board of directors, effective immediately. “Chris and Nancy will add significant value to our world-class, cross-disciplinar